C71.6 C71.5 C72.0 C75.3 C71.1 C71.2 C71.3 C71.4
Conditions
Interventions
Group 1: Observation arm: retrospective and prospective registration of all children, adolescents, and young adults with refractory, progressive or relapsed medulloblastomas, pineoblastomas, primitive
Sponsors
Universitätsklinikum Essen
Eligibility
Sex/Gender
All
Age
3 Months to No maximum
Inclusion criteria
Inclusion criteria: Medulloblastoma, pineoblastoma or other tumors of the pineal region (pineocytoma and germ cell tumors are exluded), CNS-PNETs (CNS neuroblastoma, CNS ganglioneuroblastoma, medulloepithelioma, ependymoblastoma) or ependymoma (WHO-Grade II or III) independently of the localization of the primary tumor (supratentorial, infratentorial, spinal); reference neuropathologically proven histology at new diagnosis and at relapse in case of re-operation; reference radiologically (MRI cranial and holospinal) proven refractory or progressive disease during first-line treatment or at the first or a multiple relapse and/or histologically/cytologically proven relapse within a tissue sample or a CSF sample; relapse/progress diagnosis after 01/02/2013; Age = 3 months, no upper age limit; written informed consent by the patient/the parents/the guardians for data collection and analysis
Exclusion criteria
Exclusion criteria: Enrollment into the HIT-REZ-97-Study or HIT-REZ-2005-Study Cave: The enrollment into a prospective clinical trial for relapses does not exclude the enrollment into the HIT-REZ-Registry. Refractory, progressive or relapsed diseases prior and after these prospective clinical trials can be analyzed within this registry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retrospective and prospective registration of all patients with refractory, progressive and relapsed disease of the above mentioned tumor entities wth following aims: 1. Collection and analysis of clinical data in order to evaluate the incidence of relapses 2. Collection and analysis of clinical data of relapses 3. Collection and analysis of neuropathological and molecular biological data of relapses | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality assurance of the diagnostics and of the treatment of refractory, progressive or relapsed diseases of the above mentioned tumor entities, Collection and asservation of tissue samples (Tumor, CSF samples, peripheral blood) | — |
Countries
Germany
Contacts
Public ContactRuth Mikasch
Universitätsklinikum Essen, Klinik für Kinderheilkunde III, Pädiatrische Hämatologie und Onkologie
Outcome results
None listed